27 studies found for:    " November 16, 2011":" December 16, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: NNRTI plus FTC/TDF
2 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df;   Drug: ritonavir-boosted protease inhibitor plus Truvada
3 Active, not recruiting Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen in HIV 1 Infected, Antiretroviral Treatment-Naive Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: E/C/F/TAF;   Drug: E/C/F/TDF;   Drug: Placebo to match E/C/F/TAF;   Drug: Placebo to match E/C/F/TDF
4 Completed Couple-oriented Prenatal HIV Counseling in Low and Medium HIV Prevalence Countries
Conditions: Partner HIV Testing;   Couple HIV Counseling;   Couple Communication;   HIV Incidence
Intervention: Behavioral: Couple-oriented post-test HIV counseling
5 Active, not recruiting Tobacco Assessment and Intervention With Low-Income Persons Living With HIV-AIDS (PLWHA) in Community-Based AIDS Service Organizations
Conditions: Tobacco Cessation;   HIV;   AIDS
Interventions: Behavioral: Treatment as usual;   Behavioral: AIR (Aspirations, Inspiration, Respiration)
6 Recruiting Use of Incentives to Retain Drug Users in HIV Therapy
Condition: HIV Infection
Intervention: Other: monetary reinforcer
7 Active, not recruiting Impact of Raltegravir Intensification on HIV-1-infected Subjects With Complete Viral Suppression Under Monotherapy With Protease Inhibitors
Condition: HIV-1 Infection
Interventions: Drug: Isentress® (Raltegravir, 400 mg every 12 hours);   Drug: Isentress® (Raltegravir, 400 every 12 hours)
8 Completed Men Together Making a Difference: Reducing HIV/STD Risk Behavior Among South African Men
Conditions: Human Immunodeficiency Virus Infection;   Sexually Transmitted Diseases
Interventions: Behavioral: Men Making a Difference HIV/STD Risk Reduction Intervention;   Behavioral: Health Promotion Control
9 Not yet recruiting Evaluating the Safety of Immediate Versus Deferred Isoniazid Preventive Therapy Among HIV-Infected Pregnant Women
Conditions: HIV Infections;   Tuberculosis
Interventions: Drug: Isoniazid (INH);   Drug: Placebo for isoniazid (INH)
10 Active, not recruiting Evaluating the Effectiveness of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in Treating Hepatitis C Virus (HCV) Infection in Adults With HIV and HCV Infection
Conditions: HIV Infections;   Hepatitis C
Interventions: Drug: Pegylated-Interferon Alfa 2b (PEG-IFN);   Drug: Ribavirin (RBV);   Drug: Boceprevir (BOC)
11 Not yet recruiting Evaluating the Safety of Tenofovir Vaginal Gel in HIV-Uninfected Pregnant Women
Condition: HIV Infections
Interventions: Drug: 1% tenofovir gel;   Drug: Placebo gel
12 Active, not recruiting Evaluating the Immune Response to a rAd5 HIV Vaccine Administered in Three Different Ways in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C);   Biological: rAd5 env A;   Biological: rAd5 env B;   Biological: rAd5 env C;   Biological: rAd5 gag-pol;   Biological: Placebo Vaccine
13 Active, not recruiting Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
Condition: HIV-1 Infection
Interventions: Drug: BMS-986001;   Drug: Placebo matching with BMS-986001;   Drug: Efavirenz;   Drug: Lamivudine;   Drug: Tenofovir
14 Recruiting Lipopeptide Immunisation With GTU-multiHIV Trial
Condition: HIV-1 Infection
Interventions: Biological: Placebos of GTU-multiHIV B and LIPO-5 vaccines;   Biological: GTU-multHIV B vaccine and LIPO-5 vaccine
15 Active, not recruiting
Has Results
A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in the Central Nervous System in HIV-1 Infected ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Intervention: Drug: Dolutegravir
16 Recruiting American Ginseng to Improve HIV-Associated Fatigue: A Randomized, Placebo-Controlled, Parallel Design, Multiple-Dose Clinical Trial
Condition: HIV/AIDS-associated Fatigue
Interventions: Drug: American ginseng;   Dietary Supplement: Placebo for American ginseng
17 Recruiting WHC+ (Women's Health CoOp PLUS)
Conditions: HIV;   Sexual Risk;   Sexually Transmitted Diseases;   Substance Abuse;   Violence;   Victimization
Interventions: Behavioral: Test, Treat, Retain(TTR) + Women's Health CoOp (WHC);   Biological: Test, Treat, Retain(TTR) only
18 Active, not recruiting Early HIV Therapy in Patients With High CD4 Cell Counts
Condition: HIV
Interventions: Drug: Standard ART;   Drug: Study-Provided ART
19 Unknown  Evaluation of a Tailored Virtual Intervention to Empower Persons Living With HIV for Therapy Self-management
Condition: HIV
Intervention: Behavioral: VIH-TAVIE
20 Completed Antiretroviral Drug Interaction Study in Volunteers With HIV
Conditions: HIV;   PCP;   Toxoplasmosis
Interventions: Drug: Atovaquone 750 mg twice daily;   Drug: Atovaquone 1500 mg twice daily

Previous Page Studies Shown (1-20) Next Page (21-27) Show next page of results
Indicates status has not been verified in more than two years